NCT05044091

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: the First Real-word Evidence From China

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Xiaoxiang Chen · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Homologous recombination deficiency (HRD) is an important molecular biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) which is a significant progress in the treatment of ovarian cancer. However, the proportion of HRD positive in real world and relationship of HRD status with PARPi in Chinese ovarian cancer patients remains unknown.

Detailed description

This study intends to perform HRD testing of ovarian cancer in real world from China and correlate HRD status and clinical characteristics with therapeutic outcomes.

Conditions

• Ovarian Cancer
• HRD
• PARP Inhibitor

Interventions

Type	Name	Description
DRUG	PARP inhibitor	Ovarian/fallopian tube/primary peritoneal cancer patients with PARP inhibitors according to the NCCN guideline and their instructions

Timeline

• Start date: 2021-09-15
• Primary completion: 2022-09-01
• Completion: 2023-09-01
• First posted: 2021-09-14
• Last updated: 2021-09-14

Locations

1 site across 1 country: China